<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75646">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035644</url>
  </required_header>
  <id_info>
    <org_study_id>CCEMD021</org_study_id>
    <nct_id>NCT02035644</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shijiazhuang Yiling Pharmaceutical company, LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the efficacy and safety of Jinlida granules in
      patients with inadequately controlled type-2 diabetes and dyslipidemia under life style
      intervention.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in HbA1c levels</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting, postload 30-min and 2-h plasma glucose</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting, postload 30-min and 2-h serum insulin</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose disposal rate (GDR) values from hyperinsulinemic euglycemic clamp</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incretins</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolomic parameters</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressures</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Jinlida granules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo granules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo prepared in indistinguishable granules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jinlida granules</intervention_name>
    <arm_group_label>Jinlida granules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo granules</intervention_name>
    <arm_group_label>placebo granules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age of 20-70 years;

          2. diagnosed with type 2 diabetes inadequately controlled under life style intervention
             with 3 months before screening;

          3. HbA1c ≥6.5% and ≤10.0%, and fasting plasma glucose ≥7 and ≤13.3mmol/L at baseline;

          4. diagnosed with dislipidemia with triglycerides&gt;150mg/dL (1.70mmol/L), and/or total
             cholesterol &gt;200mg/dL (5.16mmol/L), and/or LDL-c&gt;100mg/dL (2.58mmol/L)

          5. body mass index (BMI): 20&lt;BMI&lt;40 kg/m2;

        Exclusion Criteria:

          1. moderate or severe liver dysfunction, abnormal renal function;

          2. severe dysfunction of the heart;

          3. histories of acute diabetic complications including diabetic ketoacidosis or
             hyperosmolar hyperglycemic non-ketotic coma within 3 months;

          4. psychiatric disease or severe infection;

          5. pregnancy or planned pregnancy;

          6. use of any drug (including insulin) for treatment of diabetes or dyslipidemia within
             3 months;

          7. use of chronic (&gt;7 days) systemic glucocorticoid therapy within 8 weeks or receive
             growth hormone therapy within 6 months;

          8. diagnosed with type 1 diabetes, or gestational diabetes, or other specific types of
             diabetes;

          9. history of malignant tumor within 5 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guang Ning, MD, PHD</last_name>
    <phone>8621-64370045</phone>
    <phone_ext>665344</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Guang Ning</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>January 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Guang Ning</investigator_full_name>
    <investigator_title>the vice-president of Shanghai Jiao Tong University Affiliated Ruijin Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
